TD Cowen analyst Joseph Thome raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $220 from $205 and keeps a Buy rating on the shares. The firm updated its model ahead of Q4 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target raised to $230 from $220 at Truist
- Jazz Pharmaceuticals price target raised to $235 from $210 at Needham
- BofA ups Jazz Pharmaceuticals price target, says selloff ‘unwarranted’
- Closing Bell Movers: AXT Inc. slips after cutting Q4 revenue guidance
- Jazz Pharmaceuticals names Thomas Riga as Chief Business Officer